Literature DB >> 6694808

Individualization of treatment for stage I squamous cell vulvar carcinoma.

N F Hacker, J S Berek, L D Lagasse, R K Nieberg, R S Leuchter.   

Abstract

Of 177 cases of invasive squamous cell vulvar cancer seen at the University of California at Los Angeles and the City of Hope National Medical Center from 1957 to 1980, 84 (47.5%) had stage I disease. Seventy-seven patients with stage I disease (91.7%) had stromal invasion of 5 mm or less. Correlation between lymph node status and depth of invasion was as follows: 1 mm or less, none of 34 (0%); 1.1 to 2 mm, two of 19 (10.5%); 2.1 to 3 mm, two of 17 (11.8%); 3 to 5 mm, one of seven (14.3%); more than 5 mm, three of seven (42.9%). Fifty-six patients had radical vulvectomy for the primary lesion, and 28 had more conservative excision, but the incidence of local invasive recurrence (4%) was the same in each group. None of 58 patients treated with inguinal-femoral lymphadenectomy developed a groin recurrence, but three of 26 patients (11.5%) who had omission or modification of inguinal-femoral lymphadenectomy died with groin recurrence within 12 months. These data suggest that although some modification of the standard radical vulvectomy is appropriate for the primary lesion in patients with stage I disease, patients with greater than 1 mm of stromal invasion require at least an ipsilateral inguinal-femoral lymphadenectomy.

Entities:  

Mesh:

Year:  1984        PMID: 6694808

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  11 in total

Review 1.  Management of lymph nodes in the treatment of vulvar cancer.

Authors:  Toshiaki Saito; Keiji Kato
Journal:  Int J Clin Oncol       Date:  2007-06-27       Impact factor: 3.402

Review 2.  Gynaecological cancer.

Authors:  H C Kitchener
Journal:  Postgrad Med J       Date:  1999-06       Impact factor: 2.401

3.  [Surgical treatment of vulvar cancer and plastic reconstruction of vulvar defects].

Authors:  P G Knapstein; M Mahlke; W Poleska; W Zeuner
Journal:  Arch Gynecol Obstet       Date:  1989       Impact factor: 2.344

Review 4.  Vulvar lichen sclerosus in the elderly: pathophysiology and treatment update.

Authors:  Natalie A Saunders; Hope K Haefner
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

5.  Primary mucinous adenocarcinoma of the vulva, intestinal type.

Authors:  In Ho Lee; Mi Kyung Kim; Yoo Kyung Lee; Sung Ran Hong; Ki Heon Lee
Journal:  Obstet Gynecol Sci       Date:  2017-07-14

6.  Prognostic impact of reduced tumor-free margin distance on long-term survival in FIGO stage IB/II vulvar squamous cell carcinoma.

Authors:  Leonardo Micheletti; Mario Preti; Viviana Cintolesi; Elisabetta Corvetto; Silvana Privitera; Eleonora Palmese; Chiara Benedetto
Journal:  J Gynecol Oncol       Date:  2018-04-13       Impact factor: 4.401

7.  Intestinal-type adenocarcinoma of the vulva: A case study.

Authors:  Brian Kaltenecker; Robert Manos; Meagan McCall; Paul Sparzak
Journal:  Gynecol Oncol Rep       Date:  2019-03-29

8.  Intestinal-type adenocarcinoma of the Bartholin gland: A case report and literature review.

Authors:  Javier Martín-Vallejo; Patricia Molina-Bellido; Juan B Laforga; Pedro A Clemente-Pérez
Journal:  Gynecol Oncol Rep       Date:  2021-07-23

Review 9.  The giant steps in surgical downsizing toward a personalized treatment of vulvar cancer.

Authors:  Andrea Giannini; Ottavia D'Oria; Benito Chiofalo; Valentina Bruno; Ermelinda Baiocco; Emanuela Mancini; Rosanna Mancari; Cristina Vincenzoni; Giuseppe Cutillo; Enrico Vizza
Journal:  J Obstet Gynaecol Res       Date:  2021-12-28       Impact factor: 1.697

10.  Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of vulvar cancer and vaginal cancer.

Authors:  Toshiaki Saito; Tsutomu Tabata; Hitoshi Ikushima; Hiroyuki Yanai; Hironori Tashiro; Hitoshi Niikura; Takeo Minaguchi; Toshinari Muramatsu; Tsukasa Baba; Wataru Yamagami; Kazuya Ariyoshi; Kimio Ushijima; Mikio Mikami; Satoru Nagase; Masanori Kaneuchi; Nobuo Yaegashi; Yasuhiro Udagawa; Hidetaka Katabuchi
Journal:  Int J Clin Oncol       Date:  2017-11-20       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.